Newly developed retatrutide, a dual -action treatment targeting both GLP-1 and GIP receptors, is creating considerable excitement within the healthcare community. Early clinical research have shown impressive losses in physical retatrutide size and improvements in physiological markers for patients with obesity . Researchers believe this ground-br